Northern Trust Corp Purchases 3,099 Shares of Coya Therapeutics, Inc. (NASDAQ:COYA)

Northern Trust Corp boosted its position in shares of Coya Therapeutics, Inc. (NASDAQ:COYA) by 12.2% in the 4th quarter, HoldingsChannel reports. The firm owned 28,549 shares of the company’s stock after buying an additional 3,099 shares during the period. Northern Trust Corp’s holdings in Coya Therapeutics were worth $164,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the company. AIGH Capital Management LLC lifted its holdings in Coya Therapeutics by 85.0% during the 4th quarter. AIGH Capital Management LLC now owns 1,201,152 shares of the company’s stock valued at $6,883,000 after purchasing an additional 551,725 shares during the last quarter. CM Management LLC lifted its holdings in Coya Therapeutics by 11.1% during the 4th quarter. CM Management LLC now owns 160,000 shares of the company’s stock valued at $917,000 after purchasing an additional 15,941 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Coya Therapeutics by 5.8% during the 4th quarter. Geode Capital Management LLC now owns 150,576 shares of the company’s stock valued at $863,000 after purchasing an additional 8,267 shares during the last quarter. Newbridge Financial Services Group Inc. bought a new position in Coya Therapeutics during the 4th quarter valued at about $401,000. Finally, XTX Topco Ltd acquired a new stake in Coya Therapeutics in the 4th quarter valued at about $59,000. 39.75% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. Wall Street Zen cut shares of Coya Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, May 22nd. Chardan Capital restated a “buy” rating and issued a $14.00 price objective on shares of Coya Therapeutics in a research report on Tuesday, May 13th. Finally, D. Boral Capital restated a “buy” rating and issued a $18.00 price objective on shares of Coya Therapeutics in a research report on Tuesday, April 22nd. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $17.00.

Coya Therapeutics Stock Performance

Shares of NASDAQ COYA opened at $5.65 on Wednesday. The stock has a market cap of $94.50 million, a P/E ratio of -8.69 and a beta of 0.49. The firm has a 50 day moving average price of $5.83 and a 200 day moving average price of $6.06. Coya Therapeutics, Inc. has a 52-week low of $4.65 and a 52-week high of $10.24.

Coya Therapeutics (NASDAQ:COYA) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.44) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.44). The firm had revenue of $257.88 million for the quarter, compared to analyst estimates of $2.63 million. Analysts predict that Coya Therapeutics, Inc. will post -1.15 earnings per share for the current fiscal year.

Coya Therapeutics Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.